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BODIPY dyes in photodynamic therapy
Anyanee Kamkaew,a Siang Hui Lim,bc Hong Boon Lee,b Lik Voon Kiew,d
Lip Yong Chungc and Kevin Burgess*a
BODIPY dyes tend to be highly fluorescent, but their emissions can be attenuated by adding
substituents with appropriate oxidation potentials. Substituents like these have electrons to feed into
photoexcited BODIPYs, quenching their fluorescence, thereby generating relatively long-lived triplet
states. Singlet oxygen is formed when these triplet states interact with 3O2. In tissues, this causes cell
damage in regions that are illuminated, and this is the basis of photodynamic therapy (PDT). The PDT
agents that are currently approved for clinical use do not feature BODIPYs, but there are many reasons
to believe that this situation will change. This review summarizes the attributes of BODIPY dyes for PDT,
and in some related areas.
Introduction
Photodynamic therapy (PDT) is an emerging clinical modality
for treatment of neoplastic and non-malignant lesions.
Applications of PDT require a photosensitizing drug, light,
and oxygen. A series of photochemical reactions generate
singlet oxygen from the 3O2 causing tissue damage in the
regions where these three key components come together.1,2
This is a highly localized eﬀect because the half-life of singlet
oxygen is low (0.6  106 s).3 In cancer treatment, PDT can
destroy the vasculature surrounding tumour cells, and activates
immunological responses against them.4 The main attribute of
PDT is its potential for dual selectivity, i.e. preferential accu-
mulation of the photosensitizer in diseased – over normal –
tissues, and focusing light to confine damage to the targeted
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region.5 PDT is relatively non-invasive, and treatments can be
repeated without induction of resistance.2
One of the earliest clinical PDT agents is porfimer sodium
(Photofrins), a purified hematoporphyrin derivative. Porfimer
sodium is a mixture of oligomeric porphyrin units (up to eight)
linked by esters and ethers. It has received worldwide regulatory
approval in several indications, including cancers of the esophagus,
lung and bladder. Porfimer sodium is activated by red light at ca.
630 nm. Photons of this wavelength do not penetrate tissue beyond
a few millimeters, hence porfimer sodium is only suitable for
superficial tumours, or ones that can be reached via endoscopic/
fiber optic procedures. Moreover, porfimer sodium has a low
absorbance at 630 nm necessitating extended irradiation from a
high-energy source, and this often leads to complications. Another
disadvantage of porfimer sodium is that it is not cleared quickly
leading to post-treatment skin photosensitivity.6
Recognition of the disadvantages of porfimer sodium has
inspired eﬀorts to develop more eﬀective PDT photosensitizers.
Desirable properties7,8 for such agents include:
 low toxicity in the absence of light;
 low side-eﬀect profiles (e.g. skin photosensitivity and pain
after irradiation);
 appropriate lipophilic/hydrophilic balance for selective
accumulation in tumour tissue;
 high extinction coeﬃcients, particularly at long wave-
lengths for deep tissue penetration of light;
 low quantum yields for photobleaching; and
 high singlet-to-triplet intersystem crossing eﬃciencies.
Table 1 lists some newer photosensitizers that have been
approved for anti-cancer PDT along with some of their salient
physicochemical properties (comprehensive reviews on these
compounds have been published elsewhere).8 One of these
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clinically applied photosensitizers, 5-aminolevulinic acid (ALA),
is not a chromophore, but a precursor for the biosynthesis
of the protoporphyrin IX (PpIX).9 In tumours expression of
ferrochelatase, the enzyme that converts PpIX to heme, is
downregulated causing accumulation of the protoporphyrin
PDT agent.10 PpIX is rapidly cleared from the body, minimizing
the risk of skin photosensitization.11 However, ALA is hydro-
philic and has limited penetration across certain biological
barriers, so a lipophilic derivative, methyl-aminolevulinic acid,
has also been developed.12 Nevertheless, the absorption spec-
trum of PpIX at 630 nm is similar to that of porfimer sodium
hence it also gives only superficial tissue penetration in PDT.
There are some clinically approved chlorin-based photo-
sensitizers that are similar to PpIX. One of these, temoporfin
(Foscans), oﬀers improved potency, less skin photosensitivity,
and a longer maximum absorption wavelength.28 However,
temoporfin is so hydrophobic that it can precipitate upon
administration.29 Similarly verteporfin is activated by light at
690 nm, clears rapidly from the body, and only generates
short-term skin photosensitivity.30 This agent self-aggregates
in aqueous solution,31 hence it is applied in liposome formula-
tions; this mode of delivery restricts the scope of use to, so far,
age related macular degeneration caused by abnormal blood
vessel growth of the retina.32 Two other clinically approved
chlorin-based photosensitizers are mono-aspartyl-L-chlorin e6
(also known as talaporfin) and chlorin e6-polyvinylpyrrolidone.
Both these PDT agents are excellent singlet oxygen generators
Table 1 Spectroscopic and physicochemical properties of clinically approved photosensitizers
Photosensitizer lmax abs (nm) e (M
1 cm1) lmax emiss (nm) FFl FPB FD Log Po/w
Porfimer sodium
(Photofrins)
63013 300013 NA NA 5.4 
105 (PB)14
0.25 (PB + 1% TX100;
630 nm; oxygen depletion
with FFA)15
3.96
(calc.)16
Protoporphyrin
IX (Levulans)
63513 500013 630 (ex 397 nm;
PBS)17
0.011 (ex 397 nm;
PBS)17
NA 0.54 (PB + 1% TX100;
630 nm; lysozyme
inactivation; RB at 0.75)18
NA
Temoporfin
(Foscans)
650 (EtOH)19 39 000
(EtOH)19
655 (PBS)20 NA 1.54  105
(PBS + 10%
0.31 (PBS + 10% FCS;
>610 nm; DPBF; hypericin
at 0.36)21
9.2422
652 (H2O)
19 23 000
(H2O)
19
FCS)21
Verteporfin
(Visudynes)
688 (PBS +
2% TX100)23
31 200
(PBS + 2%
TX100)23
694 (PBS +
2% TX100)23
0.049 (PBS +
2% TX100)23
5.35  105
(PBS + 2%
TX100)23
0.82 (PB + 1% TX100;
692 nm; lysozyme
inactivation; MB at 0.52)18
7.76
(calc.)24
692 (PBS)23 13 500
(PBS)23
695 (PBS)23 0.002 (PBS)23 2.80  105
(PBS)23
Talaporfin
(Laserphyrins)
654 (PBS)25 40 000
(PBS)25
660 (PBS)25 NA 8.2  104
(PBS)25
0.77 (D2O, oxygen depletion
with FFA)25
1.9226
Ce6 (Photolons) 663 (PBS)27 38 000
(PBS)27
662 (PBS)27 0.18 (PBS)27 NA 0.75 (PB; 660 nm; lysozyme
inactivation; MB at 0.52)18
0.7827
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but have high photobleaching rates that reduce their PDT
eﬃciencies.33
The discussion above correctly implies that most of the clinically
relevant PDT agents are cyclic tetrapyrroles (porphyrins, chlorins,
and bacteriochlorins).34,35 These can be synthetically inaccessible,
and modifications to modulate their photophysical and biological
properties are correspondingly diﬃcult. Consequently, there is
interest in non-porphyrin photosensitizers that might be made
more easily.36–38 Phenothiazinium-based structures are a well-
known category of this type of PDT agent; they are easy to make
but have low light-to-dark toxicity ratios.39
A new class of PDT agents has emerged over the past decade:
these are based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-inda-
cene (BODIPY) core. BODIPYs have many ideal photosensitizer
characteristics including high extinction coeﬃcients, environ-
ment insensitivity, resistance to photobleaching,40 and higher
light–dark toxicity ratios41 than phenothiazinium39 PDT agents.
Several review papers have covered the role of BODIPYs as
fluorescence imaging probes,42–46 but none have focused on
derivatives for PDT. Fluorescence occurs via relaxation from
singlet excited states, so high quantum yields for fluorescence are
undesirable since this means that much of the energy absorbed on
excitation does not cross to triplet states. Consequently, BODIPYs
for PDT have to be modified to depress fluorescence and
enhance singlet-to-triplet intersystem crossing. This review
summarizes characteristics of selected members in this emerging
class of BODIPY-based PDT agents.
Halogenated BODIPYs
BODIPY derivatives are amenable to extensivemodifications around
the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene core. Most of the dyes
in this class havemany ideal characteristics of PDT agents (low dark
toxicities, cellular uptake, high extinction coeﬃcients, low quantum
yields for photobleaching) hence modifications are possible that
enable absorbance at long wavelengths. However, most BODIPY
dyes are eﬃciently excited into higher level singlet states, fluoresce
from these, and do not cross to triplets; in fact, observation of triplet
excited states in BODIPY dyes can be regarded as a novelty.47,48
Photo-damage in PDT is thought to occur predominantly via triplet
excited states, consequently BODIPY dyes for PDT tend to be
modified to enhance intersystem crossing (ISC). Spin-coupling to
heavy atoms is themost common of thesemodifications (the ‘‘heavy
atom eﬀect’’), and the one most frequently encountered is halo-
genation. Appropriate placing of heavy atoms on the BODIPY core
promotes spin–orbit coupling, hence ISC, but not energy loss from
excited states. Heavy atoms are not typically added at positions that
could disrupt the planarity of the dye as this would decrease
conjugation.
‘‘Tetramethyl-BODIPY’’ 1 does not contain a halogen, or
significantly populate triplet states on excitation, and has a
poor quantum yield (QY) for singlet oxygen (1O2) generation.
Nagano’s group was first to investigate a diiodo-analog, 2, for
singlet oxygen generation in PDT.40 Formation of 1O2 was
inferred via a near IR absorbance at 1268 nm that emerged
when 2 was excited at 514 nm. Measurements of rate and QY for
1O2-generation in a standard way, using 1,3-diphenylisobenzofuran
(DBPF), revealed high eﬃciencies for this process in both polar
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and apolar solvents. Unsurprisingly, then, compound 2 was
shown to have high light-to-dark photocytotoxicity ratios (HeLa
cells). Nagano et al. suggested that high oxidation potentials are
desirable because they may protect BODIPY from self-oxidation.
They also argued that there are potential applications of PDT in
membranes; apolar dyes like 2 are useful for studying eﬀects in
lipophilic media like this.
Two studies have compared singlet oxygen generation of a range
of iodinated BODIPYs. In the first,41 iodination of meso-aryl sub-
stituents was found to have less impact than that of core-attached
iodines. However, simple incorporation of a meso-ethylene-
carboxylic acid group as in 3 improved the rate of singlet oxygen
generation and light-induced photocytotoxicities (two of three cell
lines, the other was the same over 2). BODIPY 3 was found to
localize in the mitochondria of HSC-2 cells, and to induce G2/M
arrest about 2 h after irradiation caused apoptosis. In general the
physical parameters for singlet oxygen generation in this series
correlated with their light-induced photocytotoxicities; this is note-
worthy because such correlations are not always observed.
The second study of iodinated BODIPYs involved compounds
like 4–649 having iodine atoms at diﬀerent positions around the
BODIPY core, and measurement of QYs of oxygen generation for
selected compounds. Surprisingly, introduction of iodines at the
3- and 5-positions increases fluorescence. Flash photolysis experi-
ments showed monoexponential decay of the excited states of
these dyes, consistent with predominant recovery to the starting
material state indicative of high stability against photobleaching.
Triplet excited states for BODIPY dyes are pertinent to
triplet–triplet annihilation, hence some groups have studied
iodinated systems like the styryl-substituted one, 7, and the
dimers 8–9.50 Triplet lifetimes indicated for these structures
were measured via time-resolved spectroscopy. Estimates of
triplet quantum QY were quoted based on 1  (fluorescence
QY), but this is an overestimate because it assumes that non-
radiative decay processes are not operative.
A second study from Zhao and Li featured insertion of thio-
phene units between the iodine and the BODIPY core. This gave
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dyes 10 and 11 that have exceptionally long triplet lifetimes,
slight red-shifted absorption and fluorescence maxima, and
markedly decreased extinction coeﬃcients. These dyes also
exhibit significant fluorescence indicating incomplete ISC.51
Data specifically relating to the PDT properties of 7–11 have not
been reported.
Thiophene is less aromatic than benzene, and its HOMO/
LUMO energy levels are more suitable for conjugation with
some unsaturated fragments. Extended heterocycles containing
thiophene fragments can have similar useful characteristics.
For instance, in 12 and 13 the heteroaryl-fused ‘‘KFL-4’’ BODIPY
cores52,53 have long wavelength absorption maxima, high molar
extinction coeﬃcients, high QYs for 1O2 generation, and have
higher photostabilities than the clinically approved PDT agent
(mTHPC). Moreover, these brominated compounds have residual
fluorescence that might enable them to be used simultaneously for
imaging and PDT.
Compound 7 above is an example of a ‘‘styryl-substituted’’
BODIPY. Akkaya’s group, pioneers of this area, showed com-
pounds like this are conveniently formed via Knoevenagel
reactions since 2,7-methyl substituents on BODIPYs are slightly
acidic.54–57 In the first contribution on the PDT characteristics
of these compounds, Akkaya’s team made three brominated
systems that also have oligoethylene glycol fragments to pro-
mote water-solubilities.58 Compound 14 was the most studied
of these; it had an EC50 (conc. required for 50% of the maximal
eﬀect; excitation at 625 nm) of 200 nM and the cytotoxicity was
attributed to cell-membrane damage as indicated via fluores-
cence microscopy.
In a similar study, but featuring diiodo-BODIPY dyes, Ng
and co-workers found that 15 was the most promising of four
related potential PDT agents. They implied that this had the
lowest EC50 in the series (7 nM on HT29 carcinoma cells)
possibly because it permeated into cells, and accumulated
inside, giving the most intense fluorescence. Fluorescence
microscopy experiments indicated that this compound localized
in the endoplasmic reticulum (ER, an organelle involved in lipid
and protein synthesis).
The research on compound 15 described above was followed
by more studies on styryl-substituted BODIPYs, but this time
on ones with two diﬀerent substituents. It was hypothesized
that the unsymmetrical substitution pattern would promote
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amphiphilic character.59 Dimethylamine 16 was the most
studied in this series; it had a low EC50 (17 nM) and localized
in lysosomes, less in mitochondria, and, unlike 15, not in the
ER. Overall, the authors concluded that the functional groups
on the alkene were more important to the localization behavior
of the dyes than the lack of symmetry in the system. This paper
is an excellent reference for data on standards for singlet
oxygen generation.6,60
An attractive feature of Akkaya’s route to styryl-substituted
dyes is the diversity of aromatic aldehydes that can be con-
densed to obtain these products. For instance, the pyrene-
containing systems 17 were prepared to facilitate non-covalent,
supramolecular interactions between these compounds and
single-walled carbon nanotubes. Nanotubes of this kind are
internalized by mammalian cells, hence their interaction with
the pyrene potentially could be used for intracellular delivery of
the PDT agent. Complexation of the nanotubes with the agent
was, in the event, observed and accompanied by a small
decrease in the singlet oxygen generation eﬃciency, but cyto-
toxicity studies have not been reported so far.
Halogenated aza-BODIPY PDT agents
Aza-BODIPYs like 1861,62 have the BODIPY meso-carbon sub-
stituted by nitrogen, and this has some surprising eﬀects.
Notably, aza-BODIPYs have absorbance and fluorescence emis-
sions of around 650 and 675 nm, and these may be displaced to
even longer wavelengths in compounds containing an electron
donating group para-oriented relative to the alkene (e.g. OMe in
18). Bromination of aza-BODIPY 2,6-positions results in at least
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a four-fold reduction in fluorescence QY, and an increased
population of triplet states upon excitation giving at least 1000
diﬀerences between light and dark cytotoxicities. That para-
substituent also modulates PDT activity; for instance, the corres-
ponding system without the methoxide generated less singlet
oxygen than 18, even when present at 100 the concentration.
Molar extinction coeﬃcients of these systems are significantly better
than those of porphyrins. Unfortunately, the aqueous solubilities of
aza-BODIPYs tend to be modest so they are often delivered in
cellular assays using a cremophor (a common excipient used
in drugs to increase water solubilities, cf. a cremophor is used in
formulations of paclitaxel for the same reason).
Compound 18 has a QY for singlet oxygen generation of 74%.63
Time resolved spectroscopy revealed that its triplet quantum yield
was 72% (a lifetime of 21 ms) and that the dye was exceptionally
photostable.63 The tetraiododibromo derivative 19 had a similar
triplet QY (78%; a lifetime of 1.6 ms).64 Quantum mechanical
calculations (DFT) on these systems have been used to understand
their HOMO–LUMO levels and singlet-to-triplet energy gaps.65
Dibromo-aza-BODIPY 18 (designated ADPM06 in papers)
has been extensively studied in cells and in vivo assays. It has
a nanomolar EC50 for light-induced cytotoxicity in a range of
diﬀerent human tumour cell lines, with no discernable selectivity
for any particular type. Encouragingly, these cell types include
some drug-resistant and metastatic lines. Cells can die via necrotic
or apoptotic pathways; 18 administered at EC50 concentrations
caused apoptotic cell death. Moreover, even though cell death in
PDT can be reduced under depleted oxygen levels (e.g. hypoxia in
cancer cells), 18 retained significant activity under these condi-
tions.60 Apoptosis is initiated in PDT mediated by 18 as a result of
active oxygen species generated around the ER. This is accompa-
nied by activation of several inhibitor and executioner caspases.
Positron emission tomography studies using 18F-labeled agents
showed that a marked decrease in tumor proliferation (breast and
glioma models) occurred 24 h post-PDT treatment with 18.60 In
fact, ablation of breast tumors was observed in 71% of mice
treated with 18 at 2 mg kg1 after irradiation; this is comparable
to ‘‘cure-rates’’ for more established PDT agents in mice xenograft
models. The inherent fluorescence of 18 facilitated studies to
determine the organ distribution and clearance of this compound;
the data are consistent with that of an ideal initiator of PDT. There
was no accumulation of 18 in the skin, an important property for
PDT agents. Positron emission tomography and magnetic imaging
studies showed that this PDT agent caused a decrease in tumour-
vasculature perfusion and -metabolic activity.66
Applications of PDT are not limited to chemotherapy of
cancer; another, though rarer, use of these agents is as anti-
bacterials. O’Shea and co-workers hypothesized that the
quaternary ammonium salt 20 may implant into bacterial
membranes as a result of its positive charge and amphiphilic
character. Fluorescence studies with the non-halogenated
analog 20 demonstrated that this stains both Gram-negative
(E. coli) and -positive (S. aureus) bacteria, and yeast cells
(C. albicans) with a bias to the membrane regions. Encouragingly,
a human cell line (MDA-MB-231) showed only minimal uptake in
the same timeframe. Strong antibacterial activity on these
microbes was observed when they were irradiated with 21; total
eradication occurred at concentrations of 1–5 mg mL1.
PDT characteristics modulated by
photoinduced electron transfer (PET)
Several groups converged on the idea that photoinduced electron
transfer (PET; unfortunately, this is also a widely used abbrevia-
tion for positron emission tomography) can be used to selec-
tively quench intersystem crossing to triplet states. They have
applied this hypothesis in several diﬀerent and ingenious ways.
Some PDT side-eﬀects may arise from prolonged light
sensitivity. O’Shea recognized that aza-BODIPY dyes with a
non-conjugated but proximal amine may undergo rapid relaxa-
tion via PET processes when the amine is not protonated. How-
ever, a larger portion of the amine would be protonated in the
relatively acidic (pH 6.5–6.8) interstitial fluid that surrounds
tumours, PET would selectively diminish in those regions, and
the cytotoxic eﬀect would be greater around cancerous cells
than healthy ones.67 Dye 22 was the pivotal one used to
investigate this hypothesis. This agent was shown to generate
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more singlet oxygen in acidic than in neutral media, and an
EC50 value of 5.8 nM was recorded for light-induced cytoxicity.
However, to the best of our knowledge, photocytotoxicities of
this agent in vivo have not yet been compared with closely
related compounds that lack the amine groups, so the clinical
potential of 22 is still an open question.
Another way to use PET modulation of singlet-to-triplet
conversion is via an appropriately situated crown ether.68
Intracellular sodium ion concentrations are apparently around
3 higher in tumor cells than in healthy ones, so coordination
of these to a crown might selectively increase the PET eﬀect in
tumour cells. Thus Akkaya and co-workers combined meso-
crown ether with pyridyl–styryl substituents in molecule 23 to
sense higher sodium ion and proton concentrations in tumour
cells, respectively. The authors observed cumulative eﬀects of
both stimuli in singlet oxygen generation, but conceded that
the concentrations required to achieve a desirable response
were greater than intracellular levels; no cell studies were
reported.69
An insightful assertion by Nagano et al. was mentioned earlier
in this review: that electron withdrawing BODIPY-substituents
should protect BODIPYs from oxidation. A recent study from that
group featured a range of BODIPY dyes with diﬀerent electron
withdrawing groups at the 2- and 6-positions.70 Observation of
singlet oxygen production confirmed that these dyes are most
stable with electron withdrawing groups. A rough inverse correla-
tion between levels of singlet oxygen production and the electron
withdrawing abilities of these substituents was also noted.
Observed QYs for singlet oxygen generation were probably not high
on an absolute scale (the paper did not mention what they were)
but the study does point to a fundamental issue: singlet oxygen
generation can be modulated by tuning the oxidation potential of
the BODIPY core. This concept was used very eﬀectively in the next
study from the Nagano lab, described below.
All the applications of PDT so far target cells as a whole,
wherein the mechanisms by which the cell biology is disrupted
are not of primary importance.71 On a molecular scale, how-
ever, it is possible to use highly localized singlet oxygen gen-
eration to disable specific proteins; this is the technique of
chromophore assisted light inactivation (CALI). Nagano’s
group had the idea that a hydrophobic BODIPY-based sensitizer
might bury itself in a lipophilic cavity of a protein receptor
when brought into proximity via binding to a conjugated
ligand. This strategy is likely to be most eﬀective when singlet
oxygen production is enhanced by placing the sensitizer in a
lipophilic environment. The specific case studied was inositol
1,4,5-trisphosphate (IP3) coupled to a 2,6-diiodo-BODIPY; the
hypothesis was that ligand binding would place the dye into a
hydrophobic cavity that is easily seen in the receptor that binds
IP3 (IP3R). They showed that the electron donating substituent
in structure 25 modulated the properties of the sensitizer such
that the production of singlet oxygen was slow except in
relatively apolar solvents.
An attribute of this particular system is that binding to IP3R
gives a measurable biochemical output, i.e. increased Ca2+
concentration. Thus binding of the 2,6-diiodo-BODIPY conju-
gate gave dose-dependent release of Ca2+ with an EC50 value of
3 mM, while 2,6-diiodo-BODIPY conjugated with the enantio-
meric IP3-ligand did not give the same Ca
2+ release. Permea-
blized cells were then used to input a calcium ion sensor and
the appropriate conjugates; only the ones with an environment-
activated photosensitizer conjugated to the appropriate IP3-
ligand enantiomer gave calcium release that was negatively
modulated by treatment with light (Fig. 1).
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Halogen-free BODIPY sensitizers
There is nothing special about halogen atoms in design of BODIPY
derivatives for triplet-sensitization; any substituent with molecular
orbitals having appropriate multiplicity and energy levels might
function in this way. Surprisingly, some BODIPY fragments have
emerged as appropriate substituents to induce triplet-sensitization.
Thus, dimers of BODIPY dyes wherein the chromophores are
directly connected may, on excitation, undergo more eﬃcient ISC
to triplet states than the corresponding monomers.72
Computational studies have been used to predict orthogonal
chromophores that may give electronic mixing in the excited states
to generate triplets. Selection of the appropriate computational
method is important; here multiconfigurational self-consistent
field, MCSFF, was used. Just as predicted, bisBODIPY systems like
26were less fluorescent than their constituentmonomers, and gave
relatively high singlet QYs. An EC50 of 50 nM was measured for
human erythroleukemia cells (Fig. 2).73
Attempts to extend conjugation using the styryl approach
failed to give triplet oxygen production at higher wavelengths.
We suggest that this could be due to accelerated photobleaching
of a long-lived triplet excited state.74
Fig. 1 Binding of a functionalized BODIPY to the inositol 1,4,5-trisphosphate
receptor places the PDT agent in a hydrophobic environment where singlet
oxygen generation is favored, leading to inactivation of the protein.
Fig. 2 Excitation of bisBODIPY systems like 26 gives singlet excited states (blue
electrons), but a triplet state (red) is also favored.
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BODIPY derivative 27 is an organic triplet photosensitizer; it
is particularly interesting because no halogens or other heavier
elements are involved.75 It appears that the BODIPY fluores-
cence is quenched via intramolecular energy transfer to the
styryl protected C60-dyads, accounting for the long-lived triplet
excited state (123.2 ms) of this material.
BODIPY dyes for observing reactive oxygen
species
There are BODIPY-derivatives designed to be sensors for the
generation of reactive oxygen species. These are not necessarily
PDT agents, but they can be used to monitor consequences of
PDT treatment. One useful probe of this kind is the commer-
cially available C11-BODIPY. For example, this probe was used
to demonstrate that oxidants were present in a cell culture up to
30 min after illumination in a PDT experiment. A dark control
showed that hydrogen peroxide only activated the probe when
it was in direct contact with the cells so the researchers were
able to deduce that the reactive oxygen species involved in the
PDT experiment were not confined to peroxide anions.76
Conclusions
Many studies have focused on BODIPY core modifications to
facilitate singlet oxygen generation. The intrinsic absorption
maxima of simple BODIPY dyes (ca. 510–530 nm) are shorter
than ideal, so many of the featured modifications also aim to
extend conjugation in these molecules. For instance, Akkaya’s
methyl-BODIPY condensation reaction has been used several
times, including studies by other groups, for this purpose. One
of the most promising avenues of research, pioneered mainly
by O’Shea, centers on aza-BODIPY compounds as PDT agents;
these are less synthetically accessible, but have red-shifted
absorption maxima. In our view, aza-BODIPY agents are prob-
ably closer to clinical development than any subcategory in the
BODIPY class.
An interesting consequence of the PDT work is Nagano’s
CALI technique to eliminate selected receptors on a molecular
level. This approach is mostly intended for in vitro and cellular
studies, so wavelength of absorption is not critical. BODIPY
dyes can also be used as sensors for reactive oxygen species in
studies involving other types of agents.
A priority for future research must be to develop clinically
useful PDT agents. Possibly this will be coupled with active-
targeting. Thus it will be interesting to see future studies
featuring BODIPYs conjugated with ligands for cell-surface
receptors that are over-expressed on tumour cells. It is surprising
that we did not encounter reports of this strategy, even employ-
ing common small molecule targeting agents like RGD peptido-
mimetics and folic acid.
Abbreviations
lmax abs Absorption maxima (Q-band)
e Molar extinction coeﬃcient
lmax emiss Fluorescence emission maxima
FFl Fluorescence quantum yield
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Log Po/w Log octanol/water partition coeﬃcient
PB Phosphate buﬀer pH B 7.4
EtOH Ethanol
PBS Phosphate buﬀered saline
TX100 Triton X100
FFA Furfuryl alcohol
MB Methylene blue
RB Rose Bengal
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